Breaking News

Tweet TWEET

pSivida CEO to Discuss Sustained Delivery of Antibodies in Ophthalmology and Systemic Disease at International Symposium on

  pSivida CEO to Discuss Sustained Delivery of Antibodies in Ophthalmology and
  Systemic Disease at International Symposium on Integrated Functionalities

Business Wire

WATERTOWN, Mass. -- July 29, 2013

pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a
leader in developing sustained release drugs for treatment of back-of-the-eye
diseases, has announced that pSivida President and Chief Executive Officer,
Paul Ashton, Ph.D., will speak today at the International Symposium on
Integrated Functionalities 2013 meeting at the Hilton DFW Lakes Executive
Conference Center in Grapevine, Texas.

Dr. Ashton’s talk, “Materials Science to Bridge Biologic Breakthrough to
Therapeutic Breakthrough,” will focus on pSivida’s Tethadur™ platform and
sustained delivery of antibodies in ophthalmology and systemic disease.
Tethadur is an application of pSivida’s BioSilicon™ technology platform
designed to provide sustained delivery of large biologic molecules, including
proteins, antibodies and peptides. BioSilicon utilizes an injectable,
bioerodible, nanostructured, porous BioSilicon material for drug delivery. The
sizes of the pores in the BioSilicon material are manufactured using
nanotechnology to accommodate specific protein, peptide or antibody molecules
that are then released at a controlled, sustained rate. The technology also
has significant potential for use in many applications.

The symposium brings together leaders in fundamental and applied science in
materials integration, design and fabrication. The meeting has been sponsored
by the Materials Research Society since 1987.

About pSivida

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a controlled and
steady rate for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology systems,
Durasert™ and BioSilicon™. The injectable, sustained release micro-insert
ILUVIEN® for the treatment of chronic DME considered insufficiently responsive
to available therapies, licensed to Alimera Sciences, Inc., has received
marketing authorization in Austria, France, Germany, Portugal, Spain and the
U.K. and is awaiting authorization in Italy. Alimera has resubmitted the New
Drug Application for ILUVIEN for DME to the U.S. Food and Drug Administration.
pSivida plans to institute pivotal Phase III clinical trials for the treatment
of posterior uveitis, a chronic back-of-the-eye disease, with the same
micro-insert as ILUVIEN for DME. An investigator-sponsored clinical trial is
ongoing for an injectable, bioerodible micro-insert to treat glaucoma and
ocular hypertension. pSivida's FDA-approved Retisert® licensed to Bausch &
Lomb Incorporated provides long-term, sustained drug delivery to treat
posterior uveitis.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995: Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or developments
that we intend, expect or believe may occur in the future are forward-looking
statements. The following are some of the factors that could cause actual
results to differ materially from the anticipated results or other
expectations expressed, anticipated or implied in our forward-looking
statements: uncertainties with respect to: determination of the price and
reimbursement conditions for ILUVIEN in France; Alimera's ability to obtain
regulatory approval for, and if approved, to finance, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the U.S.; Alimera's ability to finance,
achieve additional marketing approvals, achieve appropriate pricing and
reimbursement and successfully commercialize and achieve market acceptance of,
and generate revenues to pSivida from, ILUVIEN for DME in the EU; the success
of Phase III posterior uveitis trials including efficacy, side effects and
risk/benefit profile of the posterior uveitis micro-insert and pSivida’s
ability to finance and complete the trials and receive marketing approvals;
initiation, financing and success of Latanoprost Product Phase II trials and
exercise by Pfizer of its option; development of products using Tethadur and
BioSilicon; initiation and completion of clinical trials and obtaining
regulatory approval of product candidates; adverse side effects; ability to
attain profitability; ability to obtain additional capital; further impairment
of intangible assets; fluctuations in operating results; decline in royalty
revenues; ability to, and to find partners to, develop and market products;
termination of license agreements; competition and other developments
affecting sales of products; market acceptance; protection of intellectual
property and avoiding intellectual property infringement; retention of key
personnel; product liability; consolidation in the pharmaceutical and
biotechnology industries; compliance with environmental laws; manufacturing
risks; risks and costs of international business operations; credit and
financial market conditions; legislative or regulatory changes; volatility of
stock price; possible dilution; possible influence by Pfizer; absence of
dividends; and other factors described in our filings with the SEC. Given
these uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Our forward-looking statements speak only as of
the dates on which they are made. We do not undertake any obligation to
publicly update or revise our forward-looking statements even if experience or
future changes makes it clear that any projected results expressed or implied
in such statements will not be realized.

Follow pSivida on social media:

Twitter: https://twitter.com/pSividaCorp

Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562

LinkedIn: http://www.linkedin.com/company/psivida

Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts

The President's Blog: http://www.thechairmansblog.com/paul-ashton

Contact:

IN US:
Martin E. Janis & Company, Inc.
Beverly Jedynak, 312-943-1123; 773-350-5793 (cell)
President
bjedynak@janispr.com
or
IN AUSTRALIA:
pSivida Corp.
Brian Leedman, +61 (0) 41 228 1780
Vice President, Investor Relations
brianl@psivida.com
 
Press spacebar to pause and continue. Press esc to stop.